Table 2.
Values of the indices of disease assessment in the 72 PsA patients included in the study.
| Mean (SD) | Median (range) | |
|---|---|---|
| Duration of MDA, months | 21.7 (23.1) | 12 (6–65) |
| VAS pain, 0-100 mm | 8.9 (13.9) | 4.0 (0–7) |
| VAS general health. 0–100 mm | 11.4 (17.2) | 5.0 (0–7) |
| DI-HAQ | 0.22 (0.30) | 0.125 (0–1.5) |
| ESR, mm/1st h | 10.6 (10.9) | 8 (2–41) |
| CRP, mg/dl | 0.20 (0.20) | 0.12 (0–0.81) |
| PASI | 0.43 (1.5) | 0 (0–9) |
| Tender joint count | 0.68 + 1.38 | 0 (0–7) |
| Swollen joint count | 0.07 + 0.31 | 0 (0–2) |
| LEI | 0.22 + 0.59 | 0 (0–3) |
| MASES | 0.33 + 1.09 | 0 (0–7) |
| BASDAI | 1.58 (1.51) | 1.5 (0–3.1) |
| BASFI | 1.07 (1.22) | 0.67 (0–3.5) |
| DAPSA | 2.57 (3.13) | 1.6 (0.02–8.03) |
MDA, Minimal Disease Activity; VAS, Visual Analog Scale; DI–HAQ, Disability Index of the Health Assessment Questionnaire; ESR, Erythro–sedimentation rate; CRP, C–Reactive Protein; PASI, Psoriasis Activity Severity Index; LEI, Leeds Enthesitis Index; MASES, Maastricht Ankylosing Spondyltis Enthesitis Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; DAPSA, Disease Activity index in PsA.